These findings strongly indicate that CD47 holds promise as a viable therapeutic target for gastric cancer, and underscore the considerable advantages of combining anti-CD47 treatment with anti-angiogenic therapy in the context of gastric cancer treatment. Here, CD47 is linked to gastric cancer.